Literature DB >> 9127171

Results of adjuvant therapy in resected pancreatic cancer.

A Andrén-Sandberg1, P L Bäckman, R Andersson.   

Abstract

After an apparently curative resection, most patients develop local recurrence within the resection bed. In addition, almost all develop liver metastases. This implies that the surgical resection, even if extended, seldom is enough, and that an adjuvant treatment must be effective not only against systemic spread, but also against local recurrence. However, the time schedule may be different for different types of recurrence, resulting in different time frames for the adjuvant treatment. Although extended radical operations may increase the proportion of patients who can undergo resections, the incidence of local recurrences seems unchanged. There are, however, no randomized studies yet comparing the "Standard Whipple" with more extended resection. Intraoperative radiation (IORT) has failed to demonstrate a difference in long-term survival, but there have been reports of a decreased frequency of local progression at the site of the primary tumor. Therefore, it is encouraging that IORT seems to diminish the local recurrences after radical resections. However, randomized studies are also missing for this procedure. These are today only three published studies of adjuvant chemotherapy after radical pancreaticoduodenectomy, but a few more will be finished shortly. Still, the results have not convincingly shown that modern chemotherapy with or without radiotherapy prolongs the life of the patients, and there is little evidence for improving the quality of life. However, since the results are far from satisfactory after resection, more efforts should be made to find better treatment modalities, including adjuvant protocols.

Entities:  

Mesh:

Year:  1997        PMID: 9127171     DOI: 10.1007/BF02785917

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  40 in total

1.  UICC and Japanese stage classifications for carcinoma of the pancreas.

Authors:  T Tsunoda; K Ura; T Eto; T Matsumoto; R Tsuchiya
Journal:  Int J Pancreatol       Date:  1991-04

2.  In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice.

Authors:  I E Smith; V D Courtenay; J Mills; M J Peckham
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

3.  Surgical palliation combined with synchronous therapy in pancreatic carcinoma.

Authors:  P J Kahn; Y Skornick; M Inbar; O Kaplan; S Chaichik; R Rozin
Journal:  Eur J Surg Oncol       Date:  1990-02       Impact factor: 4.424

Review 4.  Adjuvant therapy for pancreatic cancer.

Authors:  H O Douglass
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

5.  Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy.

Authors:  J L Weese; M L Nussbaum; A R Paul; P F Engstrom; L J Solin; M J Kowalyshyn; J P Hoffman
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

6.  Intraoperative radiation therapy adjuvant to resection in the treatment of pancreatic cancer.

Authors:  A Zerbi; V Fossati; D Parolini; M Carlucci; G Balzano; G Bordogna; C Staudacher; V Di Carlo
Journal:  Cancer       Date:  1994-06-15       Impact factor: 6.860

7.  Peritoneal metastases in pancreatic carcinoma.

Authors:  C F del Castillo; L Warshaw
Journal:  Hepatogastroenterology       Date:  1993-10

8.  The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma.

Authors:  J E Tepper; W U Shipley; A L Warshaw; G L Nardi; W C Wood; E L Orlow
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

9.  Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy.

Authors:  C G Willett; K Lewandrowski; A L Warshaw; J Efird; C C Compton
Journal:  Ann Surg       Date:  1993-02       Impact factor: 12.969

10.  The time of occurrence of liver metastasis in carcinoma of the pancreas.

Authors:  K Amikura; M Kobari; S Matsuno
Journal:  Int J Pancreatol       Date:  1995-04
View more
  3 in total

1.  Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer.

Authors:  H Friess; Z Lu; A Andrén-Sandberg; P Berberat; A Zimmermann; G Adler; R Schmid; M W Büchler
Journal:  Ann Surg       Date:  1998-12       Impact factor: 12.969

Review 2.  [Therapy of pancreatic adenocarcinoma].

Authors:  M Böhmig; B Wiedenmann; S Rosewicz
Journal:  Med Klin (Munich)       Date:  1999-11-15

Review 3.  Apoptosis: targets in pancreatic cancer.

Authors:  Sabine Westphal; Holger Kalthoff
Journal:  Mol Cancer       Date:  2003-01-07       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.